Melodiol Global Health (Melodiol Global Health) ROCE % : -198.22% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Melodiol Global Health ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Melodiol Global Health's annualized ROCE % for the quarter that ended in Dec. 2023 was -198.22%.

Melodiol Global Health ROCE % Historical Data

The historical data trend for Melodiol Global Health's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health ROCE % Chart

Melodiol Global Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-76.91

-146.07

-134.45

-124.08

-279.25

Melodiol Global Health Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial										-71.17	-50.71	-196.04	-292.12	-198.22

Melodiol Global Health ROCE % Calculation

Melodiol Global Health's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-17.29	/	( ( (25.629 - 10.586)	+	(12.747 - 15.407) )	/ 2 )
	=	-17.29	/	( (15.043	+	-2.66)	/ 2 )
	=	-17.29	/	6.1915
	=	-279.25 %

Melodiol Global Health's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-3.56	/	( ( (22.017 - 15.765)	+	(12.747 - 15.407) )	/ 2 )
	=	-3.56	/	( ( 6.252	+	-2.66 )	/ 2 )
	=	-3.56	/	1.796
	=	-198.22 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Melodiol Global Health (OTCPK:COPHF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Melodiol Global Health ROCE % Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Melodiol Global Health (Melodiol Global Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (OTCPK:COPHF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ME1:Australia

Address

145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009

Website

https://www.cresopharma.com

Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (Melodiol Global Health) Headlines

From GuruFocus

Halucenex Life Sciences Inc. targets Australian market following landmark TGA decision

By PRNewswire PRNewswire • 02-08-2023

Sierra Sage Herbs Acquired By Creso Pharma

By PRNewswire PRNewswire • 02-07-2022